EGFR and non-small cell lung carcinoma: Kureshi et al. utilized ML techniques, specifically an SVM and decision tree classifiers, to assess various factors in forecasting tumor response in patients with EGFR-positive NSCLC who were administered erlotinib or gefitinib.